 | Up a level |
McTeer, Matthew; Applegate, Douglas; Mesenbrink, Peter; Ratziu, Vlad; Schattenberg, Jörn M; Bugianesi, Elisabetta; Geier, Andreas; Romero Gomez, Manuel; Dufour, Jean-Francois; Ekstedt, Mattias; Francque, Sven; Yki-Jarvinen, Hannele; Allison, Michael; Valenti, Luca; Miele, Luca; Pavlides, Michael; Cobbold, Jeremy; Papatheodoridis, Georgios; Holleboom, Adriaan G; Tiniakos, Dina; ... (2024). Machine learning approaches to enhance diagnosis and staging of patients with MASLD using routinely available clinical information. PLoS ONE, 19(2), e0299487. Public Library of Science 10.1371/journal.pone.0299487
Eastell, Richard; Black, Dennis M; Boonen, Steven; Adami, Silvano; Felsenberg, Dieter; Lippuner, Kurt; Cummings, Steven R; Delmas, Pierre D; Palermo, Lisa; Mesenbrink, Peter; Cauley, Jane A (2009). Effect of once-yearly zoledronic acid 5 mg on fracture risk and change in femoral neck bone mineral density. Journal of clinical endocrinology and metabolism, 94(9), pp. 3215-3225. Chevy Chase, Md.: Endocrine Society 10.1210/jc.2008-2765
Boonen, Steven; Sellmeyer, Deborah E; Lippuner, Kurt; Orlov-Morozov, Alexander; Abrams, Ken; Mesenbrink, Peter; Eriksen, Erik F; Miller, Paul D (2008). Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney international, 74(5), pp. 641-8. New York, N.Y.: Nature Publishing Group 10.1038/ki.2008.193
